| Basics |
Biogen Inc.
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
|
| IPO Date: |
January 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$17.41B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.47 | 1.32%
|
| Avg Daily Range (30 D): |
$2.26 | 1.81%
|
| Avg Daily Range (90 D): |
$2.06 | 1.51%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.09M |
| Avg Daily Volume (30 D): |
1.27M |
| Avg Daily Volume (90 D): |
1.23M |
| Trade Size |
| Avg Trade Size (Sh.): |
109 |
| Avg Trade Size (Sh.) (30 D): |
40 |
| Avg Trade Size (Sh.) (90 D): |
40 |
| Institutional Trades |
| Total Inst.Trades: |
43,954 |
| Avg Inst. Trade: |
$5.96M |
| Avg Inst. Trade (30 D): |
$14.88M |
| Avg Inst. Trade (90 D): |
$13.55M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
8 |
| Market Closing Trades |
| Avg Closing Trade: |
$27.71M |
| Avg Closing Trade (30 D): |
$42.76M |
| Avg Closing Trade (90 D): |
$41.95M |
| Avg Closing Volume: |
132.02K |
|
|
|
|
| Financials |
| |
TTM |
Q3 2024 |
Q2 2024 |
|
Basic EPS
|
$11.1
|
$2.67
|
$4.01
|
|
Diluted EPS
|
$11.06
|
$2.66
|
$4
|
|
Revenue
|
$ 9.61B
|
$ 2.47B
|
$ 2.46B
|
|
Gross Profit
|
$ 7.26B
|
$ 1.83B
|
$ 1.92B
|
|
Net Income / Loss
|
$ 1.61B
|
$ 388.5M
|
$ 583.6M
|
|
Operating Income / Loss
|
$ 1.91B
|
$ 451M
|
$ 698.7M
|
|
Cost of Revenue
|
$ 2.35B
|
$ 638.7M
|
$ 546M
|
|
Net Cash Flow
|
$ -588.7M
|
$ -209.7M
|
$ 834.5M
|
|
PE Ratio
|
10.75
|
|
|
|
